

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of:

Ralph W. BLUME et al.

Application Number: 09/559,542

Filed: April 28, 2000

For: GUAIFENESIN SUSTAINED RELEASE FORMULATION AND TABLETS



Group Art Unit: 1614

Examiner: Not Yet Known

#5  
LB  
8/11/00

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants are submitting herewith copies of the references listed on the attached Form PTO-1449 (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.


Consideration of the foregoing plus the prompt return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action and within three months of the filing date of the application. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 02-0375.

Respectfully submitted,

BAKER BOTTS L.L.P.

By:

  
Rodger L. Tate  
Registration No. 27,399

Dated: July 25, 2000  
Baker Botts L.L.P.  
The Warner; Suite 1300  
1299 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004-2400  
(202) 639-7700 (telephone)  
(202) 639-7890 (facsimile)  
RLT/sdl